Ipsen Manufacturing
Ipsen is a biotechnological group aiming to become a leader in specialty healthcare solutions for debilitating diseases. Its strategy is supported by three franchises, neurology, endocrinology and urology-oncology.
Ipsen has a growing portfolio in prostate cancer, bladder cancer or neuro-endocrine tumours and a presence in primary care.
The group has more than 4,500 employees spread across R&D and manufacturing sites located in China, France, Ireland, the UK and the US.
Financial Data
-
31st Dec 17 Source: CRO
- €122.2 million turnover
-
€104 million
profit - 125 employees
-
31st Dec 16 Source: CRO
- €103 million turnover
-
€85.7 million
profit - 111 employees
- 5 more years available »
Ranking
By Turnover
(€122.2 million)- 428th in Top Companies
- 46th in Health
- 41st in Pharma
- 64th in Manufacturing
By Employees
(125)- 672nd in Top Companies
- 80th in Health
- 61st in Pharma
- 100th in Manufacturing
- 125
- €122.2 million
Employees
- James Byrne General Manager
Latest News
- 6:30pm Ryanair rallies as European stocks lock in fifth week of gains
- 5:59pm Spar stockpiles food products in North in plans for no-deal Brexit
- 5:43pm PTSB sells €300m of ‘bail-in-able’ senior bonds
- 5:15pm Laya Healthcare to hike plans for the second time this year
- 5:11pm Kerry lists lowest-rate Irish company bond